.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Queensland Health
Johnson and Johnson
Julphar
QuintilesIMS
Covington
Federal Trade Commission
Medtronic
Fuji

Generated: January 19, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0013407.2

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes➤ Subscribe➤ SubscribeYYREDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes➤ Subscribe➤ SubscribeYYREDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo➤ Subscribe➤ SubscribeYYREDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo➤ Subscribe➤ SubscribeYYREDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo➤ Subscribe➤ SubscribeYYTREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist